Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Piper Sandler Downgrades CNO Finl Group to Neutral

Piper Sandler downgrades CNO Finl Group (NYSE:CNO) from Overweight to Neutral.

byBenzinga Newsdesk

January 5, 2022

1 minute read

Piper Sandler downgrades CNO Finl Group (NYSE:CNO) from Overweight to Neutral.

Arcadia Biosciences Q2 Sales $3.86M Beat $2.29M Estimate

By Benzinga Newsdesk

August 11, 5:08 PM

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly sales of $3.86 million which beat the analyst consensus estimate of $2.29 million by 68.47 percent. This is a 174.59 percent increase over sales of $1.41 million the

RKDA

Benchmark Reiterates Buy on Oceaneering International, Maintains $25 Price Target

By Benzinga Newsdesk

February 27, 10:08 AM

Benchmark analyst Kurt Hallead reiterates Oceaneering International (NYSE:OII) with a Buy and maintains $25 price target.

OII

Rosenblatt Maintains Buy on Extreme Networks, Raises Price Target to $22

By Benzinga Newsdesk

October 28, 8:19 AM

Rosenblatt analyst Mike Genovese maintains Extreme Networks (NASDAQ:EXTR) with a Buy and raises the price target from $20 to $22.

EXTR

Unilever To Add This Activist Investor To Board – What’s The Catch?

By Shivani Kumaresan

May 31, 6:59 AM

Unilever PLC (NYSE:UL) has appointed Nelson Peltz, the Chief Executive Officer and founding partner of Trian Fund Management L.P., as…

GSK

Piper Sandler Downgrades CNO Finl Group to Neutral

Related Posts

Arcadia Biosciences Q2 Sales $3.86M Beat $2.29M Estimate

Benchmark Reiterates Buy on Oceaneering International, Maintains $25 Price Target

Rosenblatt Maintains Buy on Extreme Networks, Raises Price Target to $22

Unilever To Add This Activist Investor To Board – What’s The Catch?